These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37476522)

  • 1. Treatment Sequence After Initiating Biologic Therapy for Patients With Rheumatoid Arthritis in Korea: A Nationwide Retrospective Cohort Study.
    Kim MJ; Park JW; Lee SK; Jang Y; Kim S; Stoelzel M; Chua JL; Shin K
    J Rheum Dis; 2023 Jan; 30(1):26-35. PubMed ID: 37476522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis.
    Holdsworth EA; Donaghy B; Fox KM; Desai P; Collier DH; Furst DE
    Rheumatol Ther; 2021 Dec; 8(4):1637-1649. PubMed ID: 34487340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
    Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
    J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
    Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
    J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
    Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
    PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Kearsley-Fleet L; Davies R; De Cock D; Watson KD; Lunt M; Buch MH; Isaacs JD; Hyrich KL;
    Ann Rheum Dis; 2018 Oct; 77(10):1405-1412. PubMed ID: 29980575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting.
    Meissner B; Trivedi D; You M; Rosenblatt L
    J Med Econ; 2014 Apr; 17(4):259-65. PubMed ID: 24575891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study.
    Dormuth CR; Fisher A; Hudson M; Austin PC; Ernst P; Bresee L; Chateau D; Tamim H; Paterson JM; Lafrance JP; Taylor-Gjevre RM; Platt RW; Canadian Network For Observational Drug Effect Studies Cnodes Investigators
    Semin Arthritis Rheum; 2021 Dec; 51(6):1291-1299. PubMed ID: 34462128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment persistence of non-tumor necrosis factor inhibitors versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis in South Korea.
    Park JA; Lee MY; Nam JH; Shin JY; Wood R; Holbrook T; Kwon SH
    Curr Med Res Opin; 2020 Feb; 36(2):343-351. PubMed ID: 31670976
    [No Abstract]   [Full Text] [Related]  

  • 12. Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study.
    Tymms K; Kelly A; Bird P; Griffiths H; de Jager J; Littlejohn G; Louw S; Roberts L; Youssef P; Zochling J; Nichols D
    Int J Rheum Dis; 2018 Feb; 21(2):510-516. PubMed ID: 28730757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD).
    Shi Q; Li KJ; Treuer T; Wang BCM; Gaich CL; Lee CH; Wu WS; Furnback W; Tang CH
    PLoS One; 2018; 13(4):e0193489. PubMed ID: 29624580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.
    Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Gamboa NC
    Clin Rheumatol; 2021 Apr; 40(4):1273-1281. PubMed ID: 32997316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis.
    Chatzidionysiou K; Hetland ML; Frisell T; Di Giuseppe D; Hellgren K; Glintborg B; Nordström D; Peltomaa R; Aaltonen K; Trokovic N; Kristianslund EK; Kvien TK; Provan SA; Gudbjornsson B; Grondal G; Dreyer L; Kristensen LE; Jørgensen TS; Jacobsson LTH; Askling J
    J Rheumatol; 2021 Oct; 48(10):1512-1518. PubMed ID: 33649069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis.
    Wilke T; Mueller S; Lee SC; Majer I; Heisen M
    BMC Musculoskelet Disord; 2017 Aug; 18(1):332. PubMed ID: 28764705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry.
    Jung JY; Lee E; Kim JW; Suh CH; Kim HA
    Clin Exp Rheumatol; 2023 May; 41(5):1034-1041. PubMed ID: 36062753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic.
    Best JH; Vlad SC; Tominna L; Abbass I
    Rheumatol Ther; 2020 Jun; 7(2):345-355. PubMed ID: 32227284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients.
    Park EH; Shin A; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
    Joint Bone Spine; 2021 Jan; 88(1):105057. PubMed ID: 32711117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Patterns of Biologic Disease-Modifying Antirheumatic Drugs and Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in Japan: A Claims-Based Cohort Study.
    Miyashiro M; Asano T; Ishii Y; Miyazaki C; Shimizu H; Masuda J
    Drugs Real World Outcomes; 2024 Jun; 11(2):285-297. PubMed ID: 38598110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.